Vehvilainen S, Kuuliala A, Udd M, Nurmi A, Peltola K, Haglund C
Ann Surg Oncol. 2023; 31(4):2621-2631.
PMID: 38153645
PMC: 10908635.
DOI: 10.1245/s10434-023-14793-6.
Tran N, Sahai V, Griffith K, Nathan H, Kaza R, Cuneo K
Int J Radiat Oncol Biol Phys. 2019; 106(1):124-133.
PMID: 31494181
PMC: 7245020.
DOI: 10.1016/j.ijrobp.2019.08.057.
Van Sciver R, Lee M, Lee C, Lafever A, Svyatova E, Kanda K
Cancers (Basel). 2018; 10(5).
PMID: 29757973
PMC: 5977115.
DOI: 10.3390/cancers10050142.
Gilbert J, Wolpin B, Clancy T, Wang J, Mamon H, Shinagare A
Ann Oncol. 2017; 28(9):2067-2076.
PMID: 28407088
PMC: 5834155.
DOI: 10.1093/annonc/mdx180.
Chand S, OHayer K, Blanco F, Winter J, Brody J
Int J Biol Sci. 2016; 12(3):273-82.
PMID: 26929734
PMC: 4753156.
DOI: 10.7150/ijbs.14951.
A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
Burge M, ORourke N, Cavallucci D, Bryant R, Francesconi A, Houston K
HPB (Oxford). 2015; 17(7):624-31.
PMID: 25929273
PMC: 4474510.
DOI: 10.1111/hpb.12418.
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally....
Beane J, Griffin K, Levy E, Pandalai P, Wood B, Abi-Jaoudeh N
Invest New Drugs. 2014; 33(1):109-18.
PMID: 25236592
PMC: 5542811.
DOI: 10.1007/s10637-014-0157-7.
Validation of group B borderline resectable pancreatic cancer: retrospective analysis.
Oh T, Chung M, Bang S, Park S, Chung J, Song S
Gut Liver. 2014; 8(5):557-62.
PMID: 25228978
PMC: 4164249.
DOI: 10.5009/gnl13264.
Borderline resectable pancreatic cancer: definitions and management.
Lopez N, Prendergast C, Lowy A
World J Gastroenterol. 2014; 20(31):10740-51.
PMID: 25152577
PMC: 4138454.
DOI: 10.3748/wjg.v20.i31.10740.
Pancreatic cancer-improved care achievable.
Buanes T
World J Gastroenterol. 2014; 20(30):10405-18.
PMID: 25132756
PMC: 4130847.
DOI: 10.3748/wjg.v20.i30.10405.
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?.
Christians K, Tsai S, Mahmoud A, Ritch P, Thomas J, Wiebe L
Oncologist. 2014; 19(3):266-74.
PMID: 24569947
PMC: 3958454.
DOI: 10.1634/theoncologist.2013-0273.
Imaging of pancreatic ductal adenocarcinoma: State of the art.
Tamm E, Bhosale P, Vikram R, de Almeida Marcal L, Balachandran A
World J Radiol. 2013; 5(3):98-105.
PMID: 23671746
PMC: 3650210.
DOI: 10.4329/wjr.v5.i3.98.
Advanced-stage pancreatic cancer: therapy options.
Werner J, Combs S, Springfeld C, Hartwig W, Hackert T, Buchler M
Nat Rev Clin Oncol. 2013; 10(6):323-33.
PMID: 23629472
DOI: 10.1038/nrclinonc.2013.66.
Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings.
Fong Z, Tan W, Lavu H, Kennedy E, Mitchell D, Koniaris L
J Gastrointest Surg. 2013; 17(6):1098-106.
PMID: 23553385
DOI: 10.1007/s11605-013-2181-x.
Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression.
Dudeja V, Greeno E, Walker S, Jensen E
HPB (Oxford). 2013; 15(9):661-7.
PMID: 23458352
PMC: 3948532.
DOI: 10.1111/hpb.12015.
Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.
Vickers M, Pasieka J, Dixon E, McEwan S, McKay A, Renouf D
Curr Oncol. 2013; 19(6):e468-77.
PMID: 23300370
PMC: 3503677.
DOI: 10.3747/co.19.1167.
Pancreatic adenocarcinoma: Outstanding problems.
Zakharova O, Karmazanovsky G, Egorov V
World J Gastrointest Surg. 2012; 4(5):104-13.
PMID: 22655124
PMC: 3364335.
DOI: 10.4240/wjgs.v4.i5.104.
